Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021, 165(3):270-276 | DOI: 10.5507/bp.2020.043

KIR/HLA ligands immunogenetics markers associated with outcome of hepatitis B virus infection in the Bulgarian population

Viktoria Varbanovaa, Georgi Popovb, Veneta Grigorovac, Diana Petrovad, Elissaveta Naumovae, Anastasiya Mihaylovae
a Clinic of Hematology, Military Medical Academy, MHAT, Sofia, Bulgaria
b Clinic of Infection Diseases, Military Medical Academy, MHAT, Sofia, Bulgaria
c Department of Cardiac Surgery, Acibadem City Clinic, Tokuda Hospital, Sofia, Bulgaria
d Clinic of Propaedeutics in Internal Diseases, University Hospital "Alexandrovska", Medical University, Sofia, Bulgaria
e Clinic of Clinical Immunology and Stem Cell Bank, University Hospital "Alexandrovska", Medical University, Sofia, Bulgaria, mihaylova_ap@abv.bg

Background: Hepatitis B virus (HBV) infection is one of the most common infections worldwide, having negative impact on world health due to the tendency for chronification with late complications such as liver cirrhosis and hepatocellular carcinoma. Natural killer (NK) cells as part of innate antiviral defense influence the clinical course of HBV infection: elimination of the virus or chronic disease.

Aim: Therefore, we investigated the polymorphisms of the main gene systems, regulating NK-cell function: killer cell immunoglobulin-like receptors (KIRs) and their appropriate HLA class I ligands in 144 HBV infected patients (124 chronic carriers and 20 spontaneously recoved) and 126 ethnically matched healthy controls from the Bulgarian population in a case-control study.

Methods: KIRs and HLA ligands were determined by PCR-SSP or PCR high-resolution typing methods.

Results: KIR2DL5B allele variant was significantly less frequent in spontaneously recovered (SR) patients compared to healthy controls (10.0% vs. 45.5%, Pcorr=0.006). The presence of KIR3DL1*004 allele was higher in chronic HBV carriers (CH) than in controls (33.1% vs. 17.6%, Pcorr=0.036). Additionally, SR patients differed from healthy individuals by the lower frequency of HLA-Bw4Ile80 group ligands (30.0% vs 63.7%, P=0.015). Three KIR genotypes were found more frequent in healthy in comparison with HBV infected individuals: ID2 (13.5% vs 5.6%, P=0.025), KIR genotype containing 6 activating KIRs (18.0% vs 7.6%, P=0.017), and KIR genotype composed of 4 activating and 5 inhibitory KIRs (23.8% vs 5.6%, P=0.001).

Conclusion: These data suggest that inherited KIR and HLA class I ligand polymorphisms may influence the clinical course of HBV infection.

Keywords: killer immunoglobuline-like receptors, KIR HLA ligands, hepatitis B infection

Received: February 18, 2020; Revised: September 17, 2020; Accepted: September 17, 2020; Prepublished online: September 21, 2020; Published: September 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varbanova, V., Popov, G., Grigorova, V., Petrova, D., Naumova, E., & Mihaylova, A. (2021). KIR/HLA ligands immunogenetics markers associated with outcome of hepatitis B virus infection in the Bulgarian population. Biomedical papers, 165(3), 270-276. doi: 10.5507/bp.2020.043
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cristina S,Caterina S, Voller F. Emerging Trends in Epidemiology of Hepatitis B Virus Infection. J Clin Transl Hepatol 2017;5(3):272-76.
    2. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=38B5E0E5E6300DAA1792A8B312F8224A?sequence=1
    3. Kevorkyan A, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. Prevalence of HBV and HCV Among Outpatients in the Plovdiv Region of Bulgaria, 2010-2011. J Med Virol 2015;87(3):401-6. Go to original source... Go to PubMed...
    4. Pan N, Jiang W, Sun H, Miao F, Qiu J, Jin H, Xu J, Shi Q, Xie W, Zhang J. KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study. Plos One 2011;6(10):e25682. Go to original source... Go to PubMed...
    5. Pan N, Qiu J, Sun H, Miao F, Shi Q, Xu J, Jiang W, Jin H, Xie W, He Y, Zhang J. Combination of human leukocyte antigen and killer cell immunoglobulin-like receptor genetic background influences the onset age of hepatocellular carcinoma in male patients with hepatitis B virus infection. Clin Dev Immunol 2013;2013:874514. Go to original source... Go to PubMed...
    6. Auer ED, Tong TV, Amorim LM, Malheiros D, Hoan NX, Issler HC, Petzl-Erler ML, Beltrame MH, Beate A, Boldt W, Toan NL, Song LH, Velavan TP, Augusto DG. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population. IJID 2020;96:541-47. Go to original source... Go to PubMed...
    7. Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics 2000;51(4-5):268-80. Go to original source... Go to PubMed...
    8. Collona M, Samaridis S. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-8. Go to original source... Go to PubMed...
    9. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lainner LL. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol 1995;155(5):2306-10. Go to original source...
    10. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180(4):1235-42. Go to original source... Go to PubMed...
    11. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, Easterbrook P, McVicar DW, Maenaka K, Parham P, Carrington M, Dong T, Rowland-Jones S. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007;178(1):33-7. Go to original source... Go to PubMed...
    12. Marsh SGE, Parham P, Dupont B, D.E. Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H. Killer-cell immunoglobulin-like receptor(KIR) nomenclature report, 2002. Tissue Antigens 2003;62:79-86. Go to original source... Go to PubMed...
    13. Zhi-ming L, Yu-lian J, Zhao-lei F, Chun-xiao W, Zhen-fang D, Bingchang Z, Yue-ran Z. Polymorphisms of killer cell immunoglobulinlike receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat Med J 2007;48(6):800-6. Go to original source... Go to PubMed...
    14. Lu Z, Zhang B, Chen S, Gai Z, Feng Z, Liu X, Liu Y, Wen X, Li L, Jiao Y, Ma C, Shao S, Cui X, Chen G, Li J, Zhao Y.Association of KIR genotypes and haplotypes with susceptibility to chronic hepatitis B virus infection in Chinese Han population. Cell Mol Immunol 2008;5(6):457-63. Go to original source... Go to PubMed...
    15. Kibar F, Oztuk OG, Ulu A, Erken E, Inal S, Dinkci S, Kurtaran B, Tasova Y,Aksu HSZ, Yaman A. Role of KIR genes and genotypes in susceptibility to or protection against hepatitis B virus infection in a Turkish cohort. Med Sci Monit 2014;20:28-34. Go to original source... Go to PubMed...
    16. Di Bona D, Aiello A, Colomba C, Bilancia M, Accardi G, Rubino R, Giannitrapani L, Tuttolomondo A, Cascio A, Caiaffa MF, Rizzo S, Di Lorenzo G, Candore G, Duro G, Macchia L, Montalto G, Caruso C; KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group. KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection. J Viral Hepat 2017;24(9):768-75. Go to original source... Go to PubMed...
    17. Shah-Hosseini A, Jafari M, Mohammadi A, Sanaei R, Alavian SM, Doosti-Irani A, Nooradeh Keykavousi M, Tajik N. The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals. Med Microbiol Immunol 2017;206(6):463-70. Go to original source... Go to PubMed...
    18. Yindom LM, Mendy M, Bodimeade C, Chambion C, Aka P, Whittle HC, Rowland-Jones SL, Walton R. KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians. PLoS One 2017;12(11):e0188307. Go to original source... Go to PubMed...
    19. Araujo P, Gonçalves G, Latini F, Ferreira O, Porto LC, Barreto JA, Girao MJ, Diaz RS. KIR and a specific HLA-C gene are associated with susceptibility and resistance to hepatitis B virus infection in a Brazilian population. Cell Mol Immunol 2014;11(6):609-12. Go to original source... Go to PubMed...
    20. Kalyanaraman N, Thayumanavan L, Jayalakshmi M. KIR HLA association with clinical manifestations of HBV infection in Madurai, south India. J Genet 2016;95(1):13-9. Go to original source... Go to PubMed...
    21. Sorgho PA, Martinson JJ, Djigma FW, Yonli AT, Nagalo BM, Compaore TR, Obiri-Yeboah D, Diarra B, Sombie HK, Zongo AW, Ouattara AK, Soubeiga STR, Traore L, Roberts LR, Simpore J. Insights into the Interplay between KIR Gene Frequencies and Chronic HBV Infection in Burkina Faso. Mediterr J Hematol Infect Dis 2018;10(1):e2018060. Go to original source... Go to PubMed...
    22. Georgieva A. Research on immunogenetic markers related to the course of hepatitis B viral infection. Thesis, Sofia, 2016. https://www.ebi.ac.uk/ipd/kir
    23. Varbanova V, A Mihaylova, E Naumova. Olerup SSP KIR HLA ligand typing Kit. A new opportunity for KIR ligand assignment in clinical settings. C R Acad Bulg Sci 2010;63(5):713-22.
    24. Gonzalez-Galarza FF, McCabe A, Santos EJ, Jones J, Takeshita LY, Ortega-Rivera ND, Del Cid-Pavon GM, Ramsbottom K, Ghattaoraya GS, Alfirevic A, Middleton D and Jones AR. A llele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acid Research 2020;48:D783-8. Go to original source... Go to PubMed...
    25. Karabon L, Jedynak A, Giebel S, Wo³owiec D, Kielbinski M, Woszczyk D, Kapelko-Slowik K, Kuliczkowski K, Frydecka I. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011;78:129-38. Go to original source... Go to PubMed...
    26. Stelma F, Jansen L, Sinnige MJ, van Dort KA, Takkenberg RB, Janssen HL, Reesink HW, Kootstra NA. HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy. J Viral Hepat 2016;23(8):652-9. Go to original source... Go to PubMed...
    27. Pando M, Gardiner C, Gleimer M, McQueen K, Parham P. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003;171:6640-49. Go to original source... Go to PubMed...
    28. Varbanova VP, Mihailova S, Naumova E, Mihaylova AP.Certain Killer immunoglobulin like receptor (KIR)/ KIR HLA class I ligand genotypes influence NK antitumor activity in acute myelogenous leukemia but not in acute lymphoblastic leukemia. A case control leukemia association study. Turk J Haematol 2019;36(4):238-46. Go to original source... Go to PubMed...
    29. Gao S, Jiao B, Hong W, Cai C, Zhong Y, Quan Z, Chen H, Xu Y. Distribution of KIR/HLA alleles among ethnic Han Chinese patients with hepatocellular carcinoma from southern China. 2019;36(5):439-42. doi: 10.3760/cma.j.issn.1003-9406.2019.05.006 (in Chinese) Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content